Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst predicts the anticoagulants market in the US to grow at a CAGR of more than 6% by 2020. Increase in the prevalence of deep vein thrombosis (DVT) and thrombosis along with the increased inclination shown toward surgeries which require anticoagulants administration is driving the growth of this market. Moreover, the rising number of the aged population has been adding to this market’s growth as they experience higher risks of developing cardiovascular and renal diseases, leading to thromboembolic and hemorrhagic conditions. With surging incidences of venous thromboembolism and valvular heart diseases among people over 60 years, the sales of anticoagulants in the US will accelerate over the next four years.
Several studies and investigations are being conducted to exploit the use of heparin as an anti-inflammatory and antitumor agent. Researchers are coming up with frequent innovations which have led to an increase in the development of heparin drugs as novel formulations and for the treatment of new indications. For instance, Ockham Biotech is developing inhaled heparin for the treatment of airway diseases, cystic fibrosis, and asthma either alone or in combination with other drugs under various stages of development.
Oral anticoagulants occupied the largest segment of the market in 2015, in terms of ROA and accounted for more than 59% of the total market share. These drugs are used for several coagulation disorders, and primarily in the treatment of AF and DVT/PE. Factors such as approval of novel oral anticoagulants (NOACs), especially the class of factor Xa inhibitors and direct thrombin inhibitors, will augment the use of oral anticoagulants in the US.
During 2015, the Factor Xa inhibitors accounted for the largest share of the market by holding around 42% of the total market. This segment comprises direct factor Xa inhibitors, which occupy 95% share of the market as all the NOACs are included in this class. The approval of NOACs such as rivaroxaban (Xarelto), edoxaban (Savaysa), and apixaban (Eliquis) will lead to the speedy growth of this segment in the coming years.
The market is highly competitive with the presence of numerous small and large vendors. At present, the market is growing at a high pace because of the increased uptake of NOACs. Vendors are making investments in developing generic formulations for blood coagulation and other novel therapeutic areas. Recently, Daiichi Sankyo witnessed the approval of its oral anticoagulant, which has increased its market share considerably.
Key market vendors include -
Other prominent vendors in the anticoagulants market in the US are Armetheon, Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals, The Medicines Company, Urigen Pharmaceuticals, and Valeant Pharmaceuticals.
Technavio also offers customization on reports based on specific client requirement.
Anticoagulants, also known as blood thinning agents, are drugs that prevent the formation of clots and helps in the free flow of blood in the body. Though they are referred to as blood thinning agents, they do not make the blood thinner, but instead interrupts the overall process of blood coagulation. In the US, vendors like BMS/Pfizer, Janssen Pharmaceutical, Janssen Pharmaceutical, Sanofi, and Aspen will be the primary players for anticoagulants.
The report, anticoagulants market in the US, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Anticoagulants: An overview
PART 06: Reimbursement scenario
PART 07: Anticoagulant reversal agents
PART 08: Approved anticoagulants in US
PART 09: Anticoagulants pipeline portfolio
PART 10: Market landscape
PART 11: Market segmentation by ROA
PART 12: Market segmentation by drug class
PART 13: Market segmentation by application
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Appendix
PART 21: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.